<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860652</url>
  </required_header>
  <id_info>
    <org_study_id>TROG 08.03</org_study_id>
    <nct_id>NCT00860652</nct_id>
  </id_info>
  <brief_title>Radiotherapy - Adjuvant Versus Early Salvage</brief_title>
  <acronym>RAVES</acronym>
  <official_title>Radiotherapy - Adjuvant Versus Early Salvage. A Phase III Multi-centre Randomised Trial Comparing Adjuvant Radiotherapy (RT) With Early Salvage RT in Patients With Positive Margins or Extraprostatic Disease Following Radical Prostatectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Urological Society of Australia and New Zealand (USANZ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian and New Zealand Urogenital and Prostate Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trans-Tasman Radiation Oncology Group (TROG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radical prostatectomy (RP) is the most common curative approach offered to men with newly
      diagnosed prostate cancer. Unfortunately, up to half of these patients will have factors
      placing them at high risk of their cancer recurring. Having radiotherapy after RP is known to
      improve cure rates, but what is not known is whether it should be given straight after the
      operation or only when there is a rising PSA after surgery indicating active cancer.
      Immediate RT may not benefit all men, and can cause serious side effects such as bladder and
      bowel problems and impotence. International lack of consensus on the optimal timing of RT has
      resulted in varied clinical practice. This phase 3 trial will compare the two approaches.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-centre, international, randomised controlled trial with a 1:1
      allocation ratio. Patients with positive margins and/or pT3 disease will be randomised to
      adjuvant RT (Standard Arm) or active surveillance with salvage RT delivered at early relapse
      (Experimental Arm). 64 Gy in 32 fractions will be delivered to the prostate bed. QoL
      self-assessment questionnaires, Hospital Anxiety and Depression Score and toxicity will be
      assessed at baseline, the end of RT and annually for 5 years. Patients will be seen by their
      doctor 6 monthly for the first 5 years, then annually for the next 5 years. A blood test
      measuring prostate specific antigen (PSA) is done 3 monthly for the first 5 years for
      patients randomised to early salvage RT, then 6 monthly from years 5 to 10.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical failure: PSA ≥ 0.4 ng/ml and rising following RT</measure>
    <time_frame>After 160 events have been observed, expected to be 5 years after recruitment closes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Final Analysis will be after 160 events, estimated to be five years after the end of accrual</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety/Depression</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical failure-free survival</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant failure</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local failure</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the initiation of androgen ablation</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality adjusted life years</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-utility</measure>
    <time_frame>Final analysis will be after 160 events, estimated to be 5 years after end of accrual.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant Radiotherapy (RT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant Radiotherapy (64Gy in 32 Fractions to the prostate bed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Surveillance with Early SalvageRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Surveillance with Early Salvage Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Adjuvant Radiotherapy</intervention_name>
    <description>Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.</description>
    <arm_group_label>Adjuvant Radiotherapy (RT)</arm_group_label>
    <other_name>ART, Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Early Salvage Radiotherapy</intervention_name>
    <description>Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.</description>
    <arm_group_label>Active Surveillance with Early SalvageRT</arm_group_label>
    <other_name>SRT, Surveillance, Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior Radical Prostatectomy (RP) for adenocarcinoma of the prostate.

          -  Histological confirmation of adenocarcinoma of the prostate with the Gleason score
             reported (Radical Prostatectomy specimen).

          -  Patients must have at least one of the following risk factors: 1) Positive margins, 2)
             Extraprostatic extension (EPE) with or without seminal vesicle involvement (pT3a or
             pT3b)

          -  Capable of starting RT within 4 months of RP (a requirement if randomised to adjuvant
             RT arm)

          -  Most recent PSA ≤ 0.10 ng/ml following RP and prior to randomisation

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1

          -  Patient able to adhere to the specified follow-up schedule and complete the Quality of
             Life and anxiety/depression self-assessments

          -  Written informed consent obtained prior to randomisation

          -  Completion of all pre-treatment evaluations

          -  18 years and older

        Exclusion Criteria:

          -  Previous pelvic RT

          -  Androgen deprivation (AD) prior to or following RP

          -  Evidence of nodal or distant metastases

          -  Co-morbidities that would interfere with the completion of treatment and/or 5 years of
             follow-up

          -  Concurrent cytotoxic medication

          -  Hip prosthesis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Pearse, MBChB</last_name>
    <role>Study Chair</role>
    <affiliation>Trans-Tasman Radiation Oncology Group (TROG)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Kneebone</last_name>
    <role>Study Chair</role>
    <affiliation>Trans-Tasman Radiation Oncology Group (TROG)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Campbelltown Hopsital</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coffs Harbour Health Campus, NCCI</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Associates</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Clinic</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>1871</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central West Cancer Services (Orange Health)</name>
      <address>
        <city>Orange</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Port Macquarie Base Hospital, NCCI</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverina Cancer Care Centre</name>
      <address>
        <city>Wagga Wagga</city>
        <state>New South Wales</state>
        <zip>2650</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Adventist Hospital</name>
      <address>
        <city>Wahroonga</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Gold Coast</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oceania Oncology</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology - Mater Centre</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toowoomba Cancer Research Centre</name>
      <address>
        <city>Toowoomba</city>
        <state>Queensland</state>
        <zip>4350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premion</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred/WBRC</name>
      <address>
        <city>Prahan</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perth Radiation Oncology</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6014</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Radiation Oncology</name>
      <address>
        <city>Epsom</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmerston North Hospital</name>
      <address>
        <city>Palmerston North</city>
        <zip>4414</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>http://www.trog.com.au</url>
    <description>Trans Tasman Radiation Oncology Group</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncology</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Radical Prostatectomy</keyword>
  <keyword>Prior Radical Prostatectomy (RP)</keyword>
  <keyword>Histological Confirmation of adenocarcinoma of the prostate</keyword>
  <keyword>Positive margins and/or extraprostatic extension (EPE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

